Teriparatide biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)

重组人甲状旁腺激素1-34 (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameTeriparatide biosimilar (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)
Drug Alias Name特立帕肽生物仿制药 (Shanghai Fudan-Zhangjiang Bio-Pharmaceutical)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionParathyroid hormone replacements
TargetsParathyroid hormone receptor
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
China Registration ClassN/A

Develop Information

Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeH05AA02
Related LinksN/A